540726 — Trident Texofab Income Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsSpeculativeMicro CapMomentum Trap

Annual income statement for Trident Texofab, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	499	843	964	995	1,221
Cost of Revenue
Gross Profit	78.7	120	160	157	162
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	480	808	918	946	1,182
Operating Profit	19.1	35	45.3	48.5	38.2
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9.04	12.7	27.3	11.7	25.8
Provision for Income Taxes
Net Income After Taxes	3.53	9.83	22.2	10.8	25.1
Net Income Before Extraordinary Items
Net Income	3.53	9.83	22.2	10.8	25.1
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3.53	9.83	22.2	10.8	25.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.323	0.943	2.31	0.787	2.09